DOCSLIB.ORG

Combination Bupropion SR and Varenicline for Smoking Cessation: a Systematic Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combination Bupropion SR and Varenicline for Smoking Cessation: a Systematic Review The American Journal of Drug and Alcohol Abuse Encompassing All Addictive Disorders ISSN: 0095-2990 (Print) 1097-9891 (Online) Journal homepage: http://www.tandfonline.com/loi/iada20 Combination bupropion SR and varenicline for smoking cessation: a systematic review Tiffany Vogeler, Claire McClain & Kirk E. Evoy To cite this article: Tiffany Vogeler, Claire McClain & Kirk E. Evoy (2016) Combination bupropion SR and varenicline for smoking cessation: a systematic review, The American Journal of Drug and Alcohol Abuse, 42:2, 129-139, DOI: 10.3109/00952990.2015.1117480 To link to this article: http://dx.doi.org/10.3109/00952990.2015.1117480 Published online: 25 Jan 2016. Submit your article to this journal Article views: 836 View related articles View Crossmark data Citing articles: 2 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=iada20 Download by: [UCSF Library] Date: 12 July 2017, At: 17:24 AM J DRUG ALCOHOL ABUSE 2016, VOL. 42, NO. 2, 129–139 http://dx.doi.org/10.3109/00952990.2015.1117480 REVIEW Combination bupropion SR and varenicline for smoking cessation: a systematic review Tiffany Vogeler, PharmDa, Claire McClain, PharmDb, and Kirk E. Evoy, PharmD, BCACP, TTS c aPalm Beach Atlantic University, West Palm Beach, FL, USA; bTexas Children’s Hospital, Houston, TX, USA; cCollege of Pharmacy, University of Texas at Austin, San Antonio, TX, USA ABSTRACT ARTICLE HISTORY Background: Tobacco is the leading cause of preventable death in the world. Current cessation Received 3 September 2015 medications include nicotine replacement therapy (NRT), varenicline, and bupropion, while com- Revised 13 October 2015 bination therapy primarily entails NRT with either varenicline or bupropion. However, recent Accepted 3 November 2015 studies have examined varenicline and bupropion in combination. Objectives: A systematic review KEYWORDS assessing the efficacy and safety of combination varenicline and bupropion was conducted. Bupropion; varenicline; Methods: PubMed and Clinicaltrials.gov were searched using terms: “varenicline combination”, combination; smoking “bupropion combination”, “bupropion AND varenicline”, and “bupropion AND varenicline combi- cessation; review nation smoking cessation”, yielding four studies including 1193 total patients. Results: Combination therapy yielded greater efficacy than varenicline monotherapy in two randomized controlled trials and one retrospective outcomes study. One single-arm Phase II trial provided additional efficacy and safety data. Of the prospective trials, one displayed a greater 4-week smoking abstinence for weeks 8–11 with combination (39.8%) versus monotherapy (25.9%) (OR = 1.89; 95% CI = 1.07–3.35). The other demonstrated greater prolonged abstinence (continuous abstinence from week 2) at 12 weeks (OR = 1.49; 95% CI = 1.05–2.12) and 26 weeks (OR = 1.52; 95% CI = 1.04–2.22), though results were not significant at 52 weeks in this study. The retro- spective study displayed higher success rates (continuous abstinence rates at 52 weeks) with combination varenicline and bupropion (55.0%; compared to varenicline monotherapy (32.1%), p < 0.001). Subgroup analyses suggest that this combination may be more beneficial in males and ’ patients with higher baseline nicotine dependence. Conclusion: To the authors knowledge, this is the first review conducted to compile current literature on this novel pharmacotherapy combina- tion for smoking cessation. Combination bupropion SR and varenicline displayed greater efficacy in smoking cessation than varenicline monotherapy, though further safety analysis is warranted to rule out additive psychiatric adverse effects. Introduction cessation (5,6). Varenicline acts as a partial agonist at the Tobacco continues to be the leading cause of preven- α4β2 nicotinic receptor. Its efficacy in smoking cessation table death in the United States and in the world, as its is thought to be due to its high affinity and selective use is a major contributor in four out of the five leading binding to these receptors, simultaneously preventing causes of death: heart disease, cancer, chronic lower nicotine from binding (5). Bupropion SR inhibits neuro- respiratory disease, and cerebrovascular diseases (1). nal reuptake of dopamine and norepinephrine in the Smoking cessation confers tremendous immediate and reward center of the brain, which may stimulate rewards long-term health benefits (2). Current pharmacologic similar to those achieved when smoking, thus reducing treatments available to aid in smoking cessation the craving for nicotine (6). Bupropion SR is also believed include: nicotine replacement therapy (NRT), vareni- to function as a noncompetitive nicotine antagonist at the cline and bupropion sustained release (SR) (3). α4β2 receptors (7). Due to these mechanisms, varenicline Unfortunately, with current pharmacotherapy, success and bupropion SR may produce additive or synergistic rates remain low, with less than 25% of smokers effects. However, as both drugs act on the central nervous remaining abstinent one year after treatment (4). system and each feature black box warnings for suicidal Varenicline (Chantix®) and bupropion SR (Zyban®) are ideation, concern of additive side-effects could limit their non-nicotine pharmacologic treatment options approved use in combination. Recently, several clinical trials have by the Food and Drug Administration (FDA) for smoking been conducted to assess the safety and efficacy of CONTACT Kirk E. Evoy, PharmD, BCACP, TTS [email protected] College of Pharmacy, University of Texas at Austin, 5600 Babcock Rd., Apt. 5207, San Antonio, TX 78240, USA. © 2016 Taylor & Francis 130 T. VOGELER ET AL. combination varenicline and bupropion SR for smoking point-prevalence or prolonged abstinence up to a spe- cessation. This narrative review provides the evidence cified time-point. However time-points at which 7-day from each study individually, specifically focusing on point-prevalence and prolonged abstinence were efficacy in terms of point-prevalence and prolonged assessed varied between studies. Abstinence was deter- smoking abstinence as well as safety and tolerability of mined based on patient self-reporting and confirmed bupropion and varenicline in combination. Additionally, through measured exhaled CO levels in all studies, but efficacy in specific subpopulations and strengths and lim- method of self-reporting and acceptable CO levels var- itations of the identified trials are discussed. This systema- ied slightly. The fourth study assessed complete absti- tic review is the first to evaluate the total body of evidence nence rates at 52 weeks (CAR 52 weeks), measured by available relating to the use of this combination for smok- CO concentrations (10). Table 1 describes the primary ing cessation. endpoints of each trial. Two of the studies (8,9) featured a uniform defini- Methods tion of adherence (pill counts and self-reported missed doses during each visit), while a third (4) assessed Search strategy adherence, but based on daily diary entry of missed doses. The fourth study (10) did not report adherence PubMed and ClinicalTrials.gov were searched up to 5 assessment. August 2015 with the following terms specified a priori: “varenicline combination”, “bupropion combination”, “bupropion AND varenicline”, and “bupropion AND Description of included studies varenicline combination smoking cessation”. Human Two phase III trials, both published in 2014, were studies featuring a treatment arm in which patients included, one comparing combination varenicline and received both bupropion and varenicline concurrently bupropion SR versus varenicline plus placebo for 12 were included without language restrictions. Abstracts weeks in nicotine patch non-responders via an adaptive of studies identified were screened for eligibility, initi- treatment paradigm (4) and the other assessing combi- ally by two reviewers, with 100% agreement. A third nation varenicline and bupropion SR versus varenicline reviewer assessed the included studies post-agreement plus placebo for 12 weeks with subsequent follow-up by the initial reviewers. Details of the trials (timeframe, through week 52 (9). Additionally, one phase II clinical inclusion criteria, demographics, sample size, study trial, published in 2009, assessing the efficacy and safety design, outcomes, trial length and follow-up, recruit- of combination varenicline and bupropion SR, was ment methods, adverse effects, overall results and sub- included (8). The fourth study featured retrospective group analyses) were extracted and imported into a outcome research, assessing 52-week abstinence in spreadsheet (Table 1). Any discrepancies identified patients treated with varenicline monotherapy versus between the studies were discussed and reviewers patients with either bupropion, a serotonin reuptake reached a consensus before proceeding. inhibitor (SSRI), or both added to varenicline (10). Results Summary of evidence Search results Ebbert et al. conducted a phase II, open-label, one-arm The literature search yielded 1295 results. Those that trial to obtain preliminary data on the potential effec- were not conducted in humans (245) were excluded. Of tiveness and safety of combination therapy with vareni- the remaining 1050 results, only four published studies cline and bupropion SR for the treatment of tobacco included a combined varenicline and bupropion SR dependence (8). Patients were included if they met the arm.
Load more

Recommended publications
  • A Quantitative Analysis of the Value-Enhancing Effects of Nicotine
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Theses, Dissertations, and Student Research: Psychology, Department of Department of Psychology Fall 12-4-2014 A Quantitative Analysis of the Value-Enhancing Effects of Nicotine, Bupropion, and Varenicline in Male and Female Rats Scott aB rrett University of Nebraska-Lincoln, [email protected] Follow this and additional works at: http://digitalcommons.unl.edu/psychdiss Part of the Behavioral Neurobiology Commons, Biological Psychology Commons, Experimental Analysis of Behavior Commons, and the Pharmacology Commons Barrett, Scott, "A Quantitative Analysis of the Value-Enhancing Effects of Nicotine, Bupropion, and Varenicline in Male and Female Rats" (2014). Theses, Dissertations, and Student Research: Department of Psychology. 70. http://digitalcommons.unl.edu/psychdiss/70 This Article is brought to you for free and open access by the Psychology, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Theses, Dissertations, and Student Research: Department of Psychology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. A QUANTITATIVE ANALYSIS OF THE VALUE-ENHANCING EFFECTS OF NICOTINE, BUPROPION, AND VARENICLINE IN MALE AND FEMALE RATS by Scott Taylor Barrett A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Psychology Under the Supervision of Professor Rick A. Bevins Lincoln, Nebraska November, 2014 A QUANTITATIVE ANALYSIS OF THE VALUE-ENHANCING EFFECTS OF NICOTINE, BUPROPION, AND VARENICLINE IN MALE AND FEMALE RATS Scott Taylor Barrett, Ph.D. University of Nebraska, 2014 Advisor: Rick A. Bevins Smoking and tobacco dependence are serious health concerns in the United States and globally.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Specialized Rehabilitation Services for Military Service Members And
    Psychopharmacologic Approaches to Affective Disorders and Executive Dysfunction after Brain Injury Mel B. Glenn, M.D. National Medical Director, NeuroRestorative Medical Director, NeuroRestorative Massachusetts & Rhode Island Audio Check To ensure that you can hear the presentation, please take a moment to double check your audio settings. Go to the Audio tab in your GoToWebinar dashboard. • If you have selected phone call, make sure you’re dialed into the conference number. • If you are dialed in but cannot hear, try hanging up and calling back in. • If you are using only computer audio, check that your device isn’t muted. • If you’re using listening devices such as headsets, double check they are plugged in/turned on. 2 NeuroRestorative’s COVID-19 Response We are committed to protecting the health and safety of the individuals we serve, our staff, and the community. Our services are considered essential, and we are taking precautions to minimize disruption to services and keep those in our care and our team members safe. In some programs, that has meant innovating our service delivery model through Interactive Telehealth Services. We provide Interactive Telehealth Services throughout the country as an alternative to in- person services. Through Interactive Telehealth Services, we deliver the same high-quality supports as we would in-person, but in an interactive, virtual format that is HIPAA compliant and recognized by most healthcare plans and carriers. You can learn more about our COVID-19 prevention and response plan at our Update Center by visiting neurorestorative.com. 3 Disclosures • Advisor, Traumatic Brain Injury Model Systems grant, National Institute on Disability, Independent Living, and Rehabilitation Research, U.S.
    [Show full text]
  • Varenicline Criteria for Prescribing
    Varenicline Criteria Varenicline Criteria for Prescribing VA Center for Medication Safety, Tobacco Use Cessation Technical Advisory Group, Public Health Strategic Healthcare Group, VA Pharmacy Benefits Management Services, VISN Pharmacist Executives, and Medical Advisory Panel May 2008; Updated June 2008; Updated August 2008; Updated February 2010; Updated July 2011 The following recommendations are based on current medical evidence and expert opinion from clinicians. The content of the document is dynamic and will be revised as new clinical data becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. The clinician should utilize this guidance and interpret it in the clinical context of individual patient situations. Introduction: Varenicline is a second-line medication for smoking cessation in the VA health care system and should be used only for those patients who have failed an appropriate trial of nicotine replacement therapy, bupropion, or combination therapy (Combination Therapy Recommendations)(or medical contraindication to these medications) within the past year. In rare instances, varenicline has been associated with violent thoughts, intent or actions toward oneself or others. Prior to starting varenicline, patients should be screened for feelings of hopelessness, which may increase the risk of suicide once the medication is started. Patients should also be screened for current suicidal ideation or intent as well as a history of past suicide attempts. The recommended screening questions for suicide/violence risk are in Box 1, below: Patients who are positive on any of the screening questions require further evaluation by a mental health professional.
    [Show full text]
  • The Effect of Sazetidine-A and Other Nicotinic Ligands on Nicotine Controlled Goal-Tracking in Female and Male Rats
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Kentucky University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Publications Pharmaceutical Sciences 2-2017 The Effect of Sazetidine-A and Other Nicotinic Ligands on Nicotine Controlled Goal-Tracking in Female and Male Rats S. Charntikov University of New Hampshire A. M. Falco University of Nebraska - Lincoln K. Fink University of Nebraska - Lincoln Linda P. Dwoskin University of Kentucky, [email protected] See next page for additional authors Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Follow this and additional works at: https://uknowledge.uky.edu/ps_facpub Part of the Chemicals and Drugs Commons, Neuroscience and Neurobiology Commons, and the Pharmacy and Pharmaceutical Sciences Commons Authors S. Charntikov, A. M. Falco, K. Fink, Linda P. Dwoskin, and R. A. Bevins The Effect of Sazetidine-A and Other Nicotinic Ligands on Nicotine Controlled Goal- Tracking in Female and Male Rats Notes/Citation Information Published in Neuropharmacology, v. 113, part A, p. 354-366. © 2016 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC‐BY‐NC‐ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. The document available for download is the author's post-peer-review final draft of the article. Digital Object Identifier (DOI) https://doi.org/10.1016/j.neuropharm.2016.10.014 This article is available at UKnowledge: https://uknowledge.uky.edu/ps_facpub/128 HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Neuropharmacology Manuscript Author .
    [Show full text]
  • Nicotinic Acetylcholine Receptors
    nAChR Nicotinic acetylcholine receptors nAChRs (nicotinic acetylcholine receptors) are neuron receptor proteins that signal for muscular contraction upon a chemical stimulus. They are cholinergic receptors that form ligand-gated ion channels in the plasma membranes of certain neurons and on the presynaptic and postsynaptic sides of theneuromuscular junction. Nicotinic acetylcholine receptors are the best-studied of the ionotropic receptors. Like the other type of acetylcholine receptor-the muscarinic acetylcholine receptor (mAChR)-the nAChR is triggered by the binding of the neurotransmitter acetylcholine (ACh). Just as muscarinic receptors are named such because they are also activated by muscarine, nicotinic receptors can be opened not only by acetylcholine but also by nicotine —hence the name "nicotinic". www.MedChemExpress.com 1 nAChR Inhibitors & Modulators (+)-Sparteine (-)-(S)-B-973B Cat. No.: HY-W008350 Cat. No.: HY-114269 Bioactivity: (+)-Sparteine is a natural alkaloid acting as a ganglionic Bioactivity: (-)-(S)-B-973B is a potent allosteric agonist and positive blocking agent. (+)-Sparteine competitively blocks nicotinic allosteric modulator of α7 nAChR, with antinociceptive ACh receptor in the neurons. activity [1]. Purity: 98.0% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in Water, Size: 10mM x 1mL in DMSO, 100 mg 5 mg, 10 mg, 50 mg, 100 mg (±)-Epibatidine A-867744 (CMI 545) Cat. No.: HY-101078 Cat. No.: HY-12149 Bioactivity: (±)-Epibatidine is a nicotinic agonist. (±)-Epibatidine is a Bioactivity: A-867744 is a positive allosteric modulator of α7 nAChRs (IC50 neuronal nAChR agonist. values are 0.98 and 1.12 μM for human and rat α7 receptor ACh-evoked currents respectively, in X.
    [Show full text]
  • Rationale, Pharmacology and Clinical Efficacy of Partial Agonists of A4b2
    Opinion TRENDS in Pharmacological Sciences Vol.28 No.7 Rationale, pharmacology and clinical efficacy of partial agonists of a4b2 nACh receptors for smoking cessation Hans Rollema1, Jotham W. Coe2, Leslie K. Chambers1, Raymond S. Hurst1, Stephen M. Stahl4 and Kathryn E. Williams3 1 Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA 2 Department of Chemistry, Pfizer Global Research and Development, Groton, CT 06340, USA 3 Department of Clinical Development, Pfizer Global Research and Development, Groton, CT 06340, USA 4 Department of Psychiatry, University of California at San Diego, 1930 Palomar Point Way, Suite 103 Carlsbad, CA 92008, USA Most smokers repeatedly fail in their attempts to stop [7–9]. Cigarettes are particularly addictive because they smoking because of the addictive nature of the nicotine are readily available and are extremely efficient at deliver- in tobacco products. Nicotine dependence is probably ing the neuroactive components of tobacco to the brain. In mediated through the activation of multiple subtypes essence, cigarettes provide, with each inhalation, indivi- of neuronal nicotinic acetylcholine receptor (nAChR), dualized control over the amount and frequency of nicotine among which the mesolimbic a4b2 subtype has a pivotal that is delivered to the brain and, thus, over mesolimbic role. Here, we discuss the rationale for and the design of dopamine (DA) neurotransmission – a crucial element of a4b2 nAChR partial agonists as novel treatments for the response to addictive substances. The rapid and tran- tobacco addiction. Such agents are expected to exhibit sient increases in DA release in the nucleus accumbens a dual action by sufficiently stimulating a4b2-nAChR- that inhaled nicotine produces will initiate and sustain mediated dopamine release to reduce craving when compulsive substance-seeking behavior and drug depen- quitting and by inhibiting nicotine reinforcement when dence in humans, as described for other drugs of abuse.
    [Show full text]
  • Discriminative Stimulus Effects of Mecamylamine and Nicotine In
    Pharmacology, Biochemistry and Behavior 179 (2019) 27–33 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms T ⁎ Colin S. Cunningham, Megan J. Moerke, Lance R. McMahon Department of Pharmacodynamics, The University of Florida, Gainesville, FL, USA ABSTRACT Mecamylamine is a non-competitive nicotinic acetylcholine receptor (nAChR) antagonist that has been prescribed for hypertension and as an off-label smoking cessation aid. Here, we examined pharmacological mechanisms underlying the interoceptive effects (i.e., discriminative stimulus effects) of mecamylamine (5.6 mg/ kg s.c.) and compared the effects of nAChR antagonists in this discrimination assay to their capacity to block a nicotine discriminative stimulus (1.78 mg/kg s.c.) in rhesus monkeys. Central (pempidine) and peripherally restricted nAChR antagonists (pentolinium and chlorisondamine) dose-dependently substituted for the me- camylamine discriminative stimulus in the following rank order potency (pentolinium > pempidine > chlorisondamine > mecamylamine). In contrast, at equi- effective doses based on substitution for mecamylamine, only mecamylamine antagonized the discriminative stimulus effects of nicotine, i.e., pentolinium, chlor- isondamine, and pempidine did not. NMDA receptor antagonists produced dose-dependent substitution for mecamylamine with the following rank order potency (MK-801 > phencyclidine > ketamine). In contrast, behaviorally active doses of smoking cessation aids including nAChR agonists (nicotine, varenicline, and cytisine), the smoking cessation aid and antidepressant bupropion, and the benzodiazepine midazolam did not substitute for the discriminative stimulus effects of mecamylamine. These data suggest that peripheral nAChRs and NMDA receptors may contribute to the interoceptive stimulus effects produced by mecamylamine.
    [Show full text]
  • Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys
    1521-0103/366/2/397–409$35.00 https://doi.org/10.1124/jpet.118.248070 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:397–409, August 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys Sarah L. Withey,1 Michelle R. Doyle,1,2 Jack Bergman, and Rajeev I. Desai Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts Received January 27, 2018; accepted May 17, 2018 ABSTRACT Evidence suggests that the a4b2, but not the a7, subtype of the except for lobeline, the nicotinic agonists produced either full nicotinic acetylcholine receptor (nAChR) plays a key role in [(1)-epibatidine, (2)-epibatidine, and nicotine] or partial (vare- Downloaded from mediating the behavioral effects of nicotine and related drugs. nicline, cytisine, anabaseine, and isoarecolone) substitution for However, the importance of other nAChR subtypes remains (1)-epibatidine. In interaction studies with antagonists differing unclear. The present studies were conducted to examine the in selectivity, (1)-epibatidine discrimination was substan- involvement of nAChR subtypes by determining the effects of tively antagonized by mecamylamine, slightly attenuated selected nicotinic agonists and antagonists in squirrel monkeys by hexamethonium (peripherally restricted) or dihydro- b a either 1) responding for food reinforcement or 2) discriminating the -erythroidine, and not altered by methyllycaconitine ( 7 jpet.aspetjournals.org nicotinic agonist (1)-epibatidine (0.001 mg/kg) from vehicle. In selective). Varenicline and cytisine enhanced (1)-epibati- food-reinforcement studies, nicotine, (1)-epibatidine, varenicline dine’s discriminative-stimulus effects.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Chemical-Scale Studies of G Protein-Coupled Receptors And
    112 Chapter 5: An unusual pattern of ligand-receptor interactions for the α7 nicotinic acetylcholine receptor, with implications for the binding of varenicline* 5.1 Abstract The α7 nicotinic acetylcholine receptor shows broad pharmacology, complicating the development of subtype-specific nicotinic receptor agonists. Here we use unnatural amino acid mutagenesis to characterize binding to α7 by the smoking cessation drug varenicline (Chantix), an α4β2-targeted agonist that shows full efficacy and modest potency at the α7 receptor. We find that unlike binding to its target receptor, varenicline does not form a cation-π interaction with TrpB, further supporting a unique binding mode for the cationic amine of nicotinic agonists at the α7 receptor. We also evaluate binding to the complementary face of the receptor’s binding site by varenicline, the endogenous agonist acetylcholine, and the potent nicotine analog epibatidine. Interestingly, we find no evidence for functionally significant interactions involving backbone NH and CO groups thought to bind the canonical agonist hydrogen bond acceptor of the nicotinic pharmacophore, perhaps reflecting a lesser importance of this pharmacophore element for α7 binding. We also show that the Trp55 and Leu119 side chains of the binding site’s complementary face are important for the binding of the larger agonists epibatidine and varenicline, but dispensable for binding of the smaller, endogenous agonist acetylcholine. *This chapter is adapted from: Van Arnam, E. B., Blythe, E. E., Lester, H. A., and Dougherty, D. A. An unusual pattern of ligand-receptor interactions for the α7 nicotinic acetylcholine receptor, with implications for the binding of varenicline. Mol Pharmacol (2013) 84, 201-207.
    [Show full text]
  • Effectiveness of Coadministration of Varenicline, Bupropion, and Serotonin Reuptake Inhibitors in a Smoking Cessation Program in the Real-Life Setting
    NicotineNicotine & Tobacco & TobaccoResearch Research Advance Access published November 5, 2012 Brief Report Effectiveness of Coadministration of Varenicline, Bupropion, and Serotonin Reuptake Inhibitors in a Smoking Cessation Program in the Real-Life Setting Jaqueline S. Issa, M.D., Ph.D.,1 Tania Ogawa Abe, M.D.,1 Simone Moura, M.D.,1 Paulo C. J. L. Santos, Ph.D.,2 & Alexandre C. Pereira, M.D., Ph.D.2 Downloaded from 1Smoking Cessation Program Department, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil. 2Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil. Corresponding Author: Jaqueline S. Issa, M.D., Ph.D. Heart Institute, University of Sao Paulo Medical School, Rua Dr. Eneas de Carvalho Aguiar 44, 1 andar Bloco2, CEP, Sao Paulo 05403-000, Brazil. Telephone: +0-55-11-2661-5698; Fax: (0 55 11) 2661 5592; http://ntr.oxfordjournals.org/ E-mail: [email protected] Received April 24, 2012; accepted September 21, 2012 Conclusions: Our results suggest that adjuvant treatment to Abstract varenicline therapy may be associated with improved success Introduction: Varenicline has a significant impact on the ability in smoking cessation, especially in patients with nicotine with- at Universidade de São Paulo on November 6, 2012 to quit smoking. However, patients may have side effects similar drawal symptoms. These results should be tested in randomized to nicotine withdrawal symptoms. The aim of this study was to controlled trials. evaluate the effectiveness of varenicline in monotherapy or in combined therapy with bupropion and/or serotonin reuptake inhibitors (SRIs) in a specific cardiovascular smoking cessation Introduction service.
    [Show full text]